Show simple item record

dc.contributor.authorMarsh, E A
dc.contributor.authorHirst, C L
dc.contributor.authorLlewelyn, J G
dc.contributor.authorCossburn, M D
dc.contributor.authorReilly, M M
dc.contributor.authorKrishnan, A
dc.contributor.authorDoran, M
dc.contributor.authorRyan, A M
dc.contributor.authorColes, A J
dc.contributor.authorJones, J L
dc.contributor.authorRobertson, N P
dc.date.accessioned2012-01-05T13:55:32Z
dc.date.available2012-01-05T13:55:32Z
dc.date.issued2010-06
dc.identifier.citationAlemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. 2010, 257 (6):913-9 J. Neurol.en
dc.identifier.issn1432-1459
dc.identifier.pmid20049473
dc.identifier.doi10.1007/s00415-009-5437-3
dc.identifier.urihttp://hdl.handle.net/10147/200270
dc.descriptionChronic inflammatory demyelinating polyneuropathy (CIDP) is an idiopathic immune mediated neuropathy causing demyelination and conduction block thought to occur as the result of an aberrant autoimmune response resulting in peripheral nerve inflammation mediated by T cells and humoral factors. Diagnosis commonly prompts initial treatment with steroids or intravenous immunoglobulin (IVIG) on which 5-35% subsequently become dependent to maintain function. Despite a number of small scale trials, the role for alternative long-term immunosuppression remains unclear. Alemtuzumab is a humanised monoclonal antibody targeting the CD52 antigen present on the surface of lymphocytes and monocytes. A single intravenous infusion results in rapid and profound lymphopoenia lasting >12 months. We report its use and clinical outcome in a small series of patients with severe IVIG-dependent CIDP. Seven patients (4 Males; 3 Females) who had failed to respond to conventional immunosuppression were treated in 5 centres receiving 9 courses of alemtuzumab (dose range 60-150 mg). Following treatment, mean monthly IVIG use fell 26% from 202 to 149 g and IVIG administration frequency from 22 to 136 days. Two patients had prolonged remission, two patients had a partial response and no clear benefit was observed in the remaining three patients (2 Males, 1 Females). Responding patients had a younger age at onset (19.5 years) and shorter disease duration than non-responders. Three patients developed autoimmune disease following treatment. Alemtuzumab may offer an alternative treatment for a subset of early onset IVIG dependent CIDP patients failing conventional immunosuppressive agents, but concerns about toxicity may limit its use.en
dc.description.abstractChronic inflammatory demyelinating polyneuropathy (CIDP) is an idiopathic immune mediated neuropathy causing demyelination and conduction block thought to occur as the result of an aberrant autoimmune response resulting in peripheral nerve inflammation mediated by T cells and humoral factors. Diagnosis commonly prompts initial treatment with steroids or intravenous immunoglobulin (IVIG) on which 5-35% subsequently become dependent to maintain function. Despite a number of small scale trials, the role for alternative long-term immunosuppression remains unclear. Alemtuzumab is a humanised monoclonal antibody targeting the CD52 antigen present on the surface of lymphocytes and monocytes. A single intravenous infusion results in rapid and profound lymphopoenia lasting >12 months. We report its use and clinical outcome in a small series of patients with severe IVIG-dependent CIDP. Seven patients (4 Males; 3 Females) who had failed to respond to conventional immunosuppression were treated in 5 centres receiving 9 courses of alemtuzumab (dose range 60-150 mg). Following treatment, mean monthly IVIG use fell 26% from 202 to 149 g and IVIG administration frequency from 22 to 136 days. Two patients had prolonged remission, two patients had a partial response and no clear benefit was observed in the remaining three patients (2 Males, 1 Females). Responding patients had a younger age at onset (19.5 years) and shorter disease duration than non-responders. Three patients developed autoimmune disease following treatment. Alemtuzumab may offer an alternative treatment for a subset of early onset IVIG dependent CIDP patients failing conventional immunosuppressive agents, but concerns about toxicity may limit its use.
dc.language.isoenen
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAge of Onset
dc.subject.meshAnemia, Hemolytic, Autoimmune
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.subject.meshAntibodies, Neoplasm
dc.subject.meshChild
dc.subject.meshDrug Therapy, Combination
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunoglobulins, Intravenous
dc.subject.meshImmunologic Factors
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPolyradiculoneuropathy, Chronic Inflammatory Demyelinating
dc.subject.meshTime Factors
dc.subject.meshTreatment Outcome
dc.subject.meshYoung Adult
dc.titleAlemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Neurology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK.en
dc.identifier.journalJournal of neurologyen
dc.description.provinceMunster
html.description.abstractChronic inflammatory demyelinating polyneuropathy (CIDP) is an idiopathic immune mediated neuropathy causing demyelination and conduction block thought to occur as the result of an aberrant autoimmune response resulting in peripheral nerve inflammation mediated by T cells and humoral factors. Diagnosis commonly prompts initial treatment with steroids or intravenous immunoglobulin (IVIG) on which 5-35% subsequently become dependent to maintain function. Despite a number of small scale trials, the role for alternative long-term immunosuppression remains unclear. Alemtuzumab is a humanised monoclonal antibody targeting the CD52 antigen present on the surface of lymphocytes and monocytes. A single intravenous infusion results in rapid and profound lymphopoenia lasting >12 months. We report its use and clinical outcome in a small series of patients with severe IVIG-dependent CIDP. Seven patients (4 Males; 3 Females) who had failed to respond to conventional immunosuppression were treated in 5 centres receiving 9 courses of alemtuzumab (dose range 60-150 mg). Following treatment, mean monthly IVIG use fell 26% from 202 to 149 g and IVIG administration frequency from 22 to 136 days. Two patients had prolonged remission, two patients had a partial response and no clear benefit was observed in the remaining three patients (2 Males, 1 Females). Responding patients had a younger age at onset (19.5 years) and shorter disease duration than non-responders. Three patients developed autoimmune disease following treatment. Alemtuzumab may offer an alternative treatment for a subset of early onset IVIG dependent CIDP patients failing conventional immunosuppressive agents, but concerns about toxicity may limit its use.


This item appears in the following Collection(s)

Show simple item record